Nephrogenic systemic fibrosis and gadolinium-enhanced magnetic resonance imaging: does a US Food and Drug Administration alert influence practice patterns in CKD?
Martin
Diego R
DR
D016907:Adverse Drug Reaction Reporting Systems; D002908:Chronic Disease; D003287:Contrast Media / Q000009:adverse effects*; D005682:Gadolinium / Q000009:adverse effects*; D006801:Humans; D007674:Kidney Diseases / Q000503:physiopathology; D008279:Magnetic Resonance Imaging; D054989:Nephrogenic Fibrosing Dermopathy / Q000139:chemically induced*; D010818:Practice Patterns, Physicians' / Q000592:standards*; D014481:United States; D014486:United States Food and Drug Administration
D003287:Contrast Media; D005682:Gadolinium